MSC treatment 02

MSC treatment 02 refers to a specific high-dose regimen (6×10^6 cells/kg) of mesenchymal stem cells (MSCs) being investigated by the Sixth Affiliated Hospital, Sun Yat-sen University, for the treatment of refractory Crohn's disease. Mesenchymal stem cells are multipotent stromal cells that possess significant immunomodulatory and anti-inflammatory properties. In the context of Crohn's disease, they are thought to migrate to sites of inflammation and secrete bioactive factors—such as TGF-β, IL-10, and PGE2—that suppress overactive immune responses, promote regulatory T-cell (Treg) differentiation, and facilitate mucosal healing. This specific treatment arm is part of a Phase II clinical trial evaluating the safety and efficacy of MSCs as an adjunctive therapy to standard treatments like infliximab or azathioprine.

Other names

MSC treatment 02-Sixth Affiliated Hospital, Sun Yat-sen University-Crohn's diseaseMesenchymal stem cellsMSC therapy